Ubrelvy is not currently available as a generic medication. The drug, which is used to treat migraine, is still under patent protection. [1]
When does Ubrelvy's patent expire?
The primary patent for Ubrelvy is set to expire in 2037. [1] However, there can be multiple patents associated with a drug, including those for its formulation or method of use, which may expire at different times. Information on specific patent expiry dates can be found on resources like DrugPatentWatch.com. [1]
Can a generic version of Ubrelvy be developed before patent expiry?
The development of a generic version of a drug before its patent expires typically requires a successful patent challenge. Companies may file Paragraph IV certifications, asserting that the patents protecting the branded drug are invalid, unenforceable, or will not be infringed by the generic product. [2] If a generic company successfully challenges the patent, it may be able to launch its product earlier.
Who makes Ubrelvy?
Ubrelvy is manufactured by AbbVie. [1]
How does Ubrelvy work for migraines?
Ubrelvy belongs to a class of drugs called calcitonin gene-related peptide (CGRP) receptor antagonists. It works by blocking the activity of CGRP, a molecule that is believed to play a role in migraine pain and inflammation. [3]
What are the alternatives to Ubrelvy?
Other CGRP-targeting medications are available for migraine treatment, including other oral CGRP antagonists and CGRP monoclonal antibodies. [3] Additionally, traditional migraine treatments like triptans and non-steroidal anti-inflammatory drugs (NSAIDs) are also used.
What is the cost of Ubrelvy?
As a branded medication without generic alternatives, Ubrelvy's cost can be significant. Pricing can vary based on insurance coverage, pharmacy, and whether patient assistance programs are utilized.
---
Sources
[1] https://drugpatentwatch.com/
[2] https://www.law.cornell.edu/cfr/text/21/314.50
[3] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/ubrelvy-ubrogepant-drug-safety-communication-fda-evaluating-potential-risk-drug-interactions